HRTX
NASDAQHeron Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks39+150%
2026-03-012026-08-23
Mix2190d
- Insider10(48%)
- SEC Filings6(29%)
- Analyst2(10%)
- Earnings2(10%)
- Other1(5%)
Latest news
25 items- SECHeron Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- ANALYSTHeron Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Heron Therapeutics from Buy to Neutral
- INSIDERChief Operating Officer Hensley Mark Earl converted options into 31,250 shares and covered exercise/tax liability with 8,888 shares, increasing direct ownership by 15% to 170,901 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- SECSEC Form 10-Q filed by Heron Therapeutics Inc.10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- SECHeron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- PRHeron Therapeutics Announces Second Quarter 2026 Financial Results– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF® net revenue grew 35% and APONVIE® net revenue grew 74% year-over-year – Amended credit facility with Hercules Capital: financial covenants reset through 2027, and outstanding principal to be reduced by a total potential reduction of $17.5 million — $13.5 million at execution and a potential further reduction of $4 million scheduled on or before September 15, 2026 – Withdrew full-year 2026 financial guidance CARY, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the
- INSIDERChief Operating Officer Hensley Mark Earl converted options into 11,769 shares, increasing direct ownership by 9% to 148,539 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- INSIDEREVP, Chief Development Officer Forbes William P converted options into 23,463 shares and covered exercise/tax liability with 6,674 shares, increasing direct ownership by 7% to 241,173 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- INSIDEREVP, Chief Financial Officer Duarte Ira covered exercise/tax liability with 7,176 shares and converted options into 25,229 shares, increasing direct ownership by 7% to 281,899 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- INSIDERChief Executive Officer Collard Craig A converted options into 84,810 shares, increasing direct ownership by 11% to 856,492 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- PRHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the I
- INSIDERChief Executive Officer Collard Craig A converted options into 13,797 shares, increasing direct ownership by 2% to 771,682 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- INSIDEREVP, Chief Development Officer Forbes William P converted options into 3,874 shares and covered exercise/tax liability with 1,101 shares, increasing direct ownership by 1% to 224,384 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- INSIDEREVP, Chief Financial Officer Duarte Ira converted options into 3,874 shares and covered exercise/tax liability with 1,101 shares, increasing direct ownership by 1% to 263,846 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- SECHeron Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- INSIDEREVP, Chief Financial Officer Duarte Ira converted options into 12,500 shares and covered exercise/tax liability with 3,555 shares, increasing direct ownership by 4% to 261,073 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- SECHeron Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- INSIDEREVP, Chief Development Officer Forbes William P converted options into 12,500 shares, increasing direct ownership by 6% to 221,611 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
- ANALYSTHeron Therapeutics downgraded by NeedhamNeedham downgraded Heron Therapeutics from Buy to Hold
- SECHeron Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- PRU.S. District Court Issues Decision Regarding CINVANTI® PatentsCARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC ("Azurity"), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable emul
- SECSEC Form 10-Q filed by Heron Therapeutics Inc.10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- SECHeron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
- PRHeron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms GuidanceQ1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthcare Corporation in CINVANTI® patent litigationReaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million Adjusted EBITDA CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates. "Despite typical first-quarter seasonality and unusual weather-related dis
- INSIDERChief Operating Officer Hensley Mark Earl converted options into 125,000 shares, increasing direct ownership by 1,062% to 136,770 units (SEC Form 4)4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
HRTX FAQ
6 questionsWhat does Heron Therapeutics Inc. do?
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy...Where does HRTX stock trade?
Heron Therapeutics Inc. (HRTX) is listed on NASDAQ.What sector and industry is HRTX in?
Heron Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HRTX?
Heron Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-08-11. Recent price targets range from $500.00 to $700.00.What companies are similar to HRTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HRTX side-by-side with any of them on Quantisnow.How can I track HRTX on Quantisnow?
Quantisnow aggregates Heron Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HRTX to receive live email and push alerts on every new disclosure.